Copyright
©The Author(s) 2023.
World J Gastroenterol. Dec 7, 2023; 29(45): 5962-5973
Published online Dec 7, 2023. doi: 10.3748/wjg.v29.i45.5962
Published online Dec 7, 2023. doi: 10.3748/wjg.v29.i45.5962
Table 1 Characteristics of study participants according to the quartiles of muscle strength
Q1 | Q2 | Q3 | Q4 | P for trend | |
N (unweighted) | 4305 | 4347 | 4397 | 4300 | |
Age (yr) | 55.9 ± 0.4 | 49.2 ± 0.4 | 44.6 ± 0.3 | 39.9 ± 0.2 | < 0.001 |
Sex (men) | 45.2 (1.0) | 45.9 (0.9) | 46.2 (0.9) | 48.0 (0.9) | 0.172 |
Current smoker | 13.6 (0.7) | 16.6 (0.7) | 17.7 (0.7) | 20.3 (0.8) | < 0.001 |
Physical activity | 38.5 (1.0) | 46.4 (1.0) | 51.1 (0.9) | 53.1 (0.9) | < 0.001 |
Income (lowest quartile) | 28.8 (1.0) | 16.5 (0.7) | 10.7 (0.6) | 8.0 (0.5) | < 0.001 |
Education (≤ 12 yr) | 45.4 (1.2) | 28.1 (0.9) | 16.9 (0.7) | 8.5 (0.5) | < 0.001 |
BMI (kg/m2) | 26.0 ± 0.1 | 24.7 ± 0.1 | 23.5 ± 0.1 | 21.8 ± 0.1 | < 0.001 |
Waist circumference (cm) | 88.0 ± 0.2 | 84.0 ± 0.2 | 80.5 ± 0.2 | 76.3 ± 0.2 | < 0.001 |
Handgrip strength (kg) | 21.8 ± 0.2 | 27.8 ± 0.2 | 31.2 ± 0.2 | 35.6 ± 0.2 | < 0.001 |
Muscle strength (handgrip strength/body mass index) | 0.8 ± 0.01 | 1.1 ± 0.01 | 1.3 ± 0.01 | 1.6 ± 0.01 | < 0.001 |
Systolic BP (mmHg) | 122.7 ± 0.4 | 118.2 ± 0.3 | 115.2 ± 0.3 | 112.1 ± 0.3 | < 0.001 |
Diastolic BP (mmHg) | 75.3 ± 0.2 | 75.8 ± 0.2 | 75.2 ± 0.2 | 74.2 ± 0.2 | < 0.001 |
AST (IU/L) | 24.5 ± 0.2 | 23.1 ± 0.2 | 21.5 ± 0.2 | 20.2 ± 0.1 | < 0.001 |
ALT (IU/L) | 26.0 ± 0.5 | 24.2 ± 0.4 | 21.0 ± 0.3 | 18.4 ± 0.2 | < 0.001 |
Total cholesterol (mg/dL) | 191.4 ± 0.7 | 194.3 ± 0.7 | 194.1 ± 0.6 | 188.8 ± 0.6 | < 0.001 |
HDL-C (mg/dL) | 47.4 ± 0.2 | 49.9 ± 0.2 | 51.6 ± 0.2 | 54.0 ± 0.2 | < 0.001 |
LDL-C (mg/dL) | 115.0 ± 0.7 | 116.9 ± 0.6 | 116.5 ± 0.6 | 112.3 ± 0.5 | < 0.001 |
Triglycerides (mg/dL) | 145.6 ± 2.0 | 137.5 ± 2.0 | 130.1 ± 1.9 | 112.5 ± 1.6 | < 0.001 |
Fasting glucose (mg/dL) | 106.1 ± 0.5 | 100.8 ± 0.4 | 97.6 ± 0.4 | 93.8 ± 0.3 | < 0.001 |
HbA1c (%) | 5.9 ± 0.02 | 5.7 ± 0.01 | 5.6 ± 0.01 | 5.4 ± 0.01 | < 0.001 |
hs-CRP (mg/L) | 1.7 ± 0.04 | 1.2 ± 0.04 | 1.1 ± 0.03 | 0.8 ± 0.03 | < 0.001 |
Obesity | 56.7 (0.9) | 44.0 (1.0) | 28.7 (0.8) | 11.6 (0.6) | < 0.001 |
Hypertension | 45.4 (1.0) | 30.5 (0.8) | 21.5 (0.7) | 12.4 (0.6) | < 0.001 |
Diabetes mellitus | 22.5 (0.7) | 13.1 (0.6) | 7.8 (0.4) | 3.9 (0.3) | < 0.001 |
Dyslipidemia | 31.8 (0.9) | 28.1 (0.9) | 21.2 (0.7) | 14.1 (0.6) | < 0.001 |
Table 2 Odds ratios (95% confidence intervals) of metabolic dysfunction-associated fatty liver disease according to the categories of muscle strength
Muscle strength | Model 1 | Model 2 | Model 3 |
Total | |||
Q1 | 3.63 (3.34–3.95) | 3.24 (2.94–3.58) | 1.92 (1.70–2.16) |
Q2–Q4 | 1 (reference) | 1 (reference) | 1 (reference) |
P value | |||
Q1 | 9.12 (7.98–10.41) | 8.61 (7.41–10.01) | 3.12 (2.64–3.69) |
Q2 | 4.92 (4.29–5.64) | 4.75 (4.10–5.50) | 2.19 (1.85–2.58) |
Q3 | 2.48 (2.17–2.84) | 2.42 (2.10–2.78) | 1.41 (1.22–1.65) |
Q4 | 1 (reference) | 1 (reference) | 1 (reference) |
P for trend | < 0.001 | < 0.001 | < 0.001 |
Men | |||
Q1 | 3.51 (3.02–4.09) | 3.31 (2.80–3.90) | 2.05 (1.70–2.47) |
Q2–Q4 | 1 (reference) | 1 (reference) | 1 (reference) |
P value | < 0.001 | < 0.001 | |
Q1 | 7.30 (5.67–9.39) | 7.20 (5.52–9.38) | 2.88 (2.20–3.78) |
Q2 | 3.68 (2.83–4.78) | 3.68 (2.82–4.80) | 1.75 (1.32–2.31) |
Q3 | 2.02 (1.54–2.66) | 2.03 (1.55–2.68) | 1.23 (0.93–1.63) |
Q4 | 1 (reference) | 1 (reference) | 1 (reference) |
P for trend | < 0.001 | < 0.001 | < 0.001 |
Women | |||
Q1 | 4.20 (3.74–4.71) | 3.17 (2.79–3.60) | 1.76 (1.47–2.10) |
Q2–Q4 | 1 (reference) | 1 (reference) | 1 (reference) |
P value | < 0.001 | < 0.001 | < 0.001 |
Q1 | 11.76 (9.87–14.02) | 9.14 (7.56–11.05) | 3.09 (2.43–3.92) |
Q2 | 6.09 (5.15–7.20) | 5.30 (4.47–6.30) | 2.52 (2.05–3.10) |
Q3 | 2.76 (2.34–3.26) | 2.59 (2.20–3.06) | 1.52 (1.25–1.85) |
Q4 | 1 (reference) | 1 (reference) | 1 (reference) |
P for trend | < 0.001 | < 0.001 | < 0.001 |
Table 3 Subgroup analysis for the association between muscle strength and metabolic dysfunction-associated fatty liver disease
Muscle strength | OR (95%CI) | P for interaction | |
Sex | 0.126 | ||
Men | Q2–Q4 | 1 (reference) | |
Q1 | 2.05 (1.70–2.47) | ||
Women | Q2–Q4 | 1 (reference) | |
Q1 | 1.76 (1.47–2.10) | ||
Age | 0.057 | ||
< 65 yr | Q2–Q4 | 1 (reference) | |
Q1 | 1.97 (1.70–2.29) | ||
≥ 65 yr | Q2–Q4 | 1 (reference) | |
Q1 | 1.74 (1.44–2.09) | ||
Obesity | 0.264 | ||
No | Q2–Q4 | 1 (reference) | |
Q1 | 1.63 (1.36–1.96) | ||
Yes | Q2–Q4 | 1 (reference) | |
Q1 | 2.09 (1.75–2.48) | ||
Diabetes mellitus | 0.622 | ||
No | Q2–Q4 | 1 (reference) | |
Q1 | 1.97 (1.72–2.26) | ||
Yes | Q2–Q4 | 1 (reference) | |
Q1 | 1.71 (1.33–2.22) |
Table 4 Association between muscle strength and probable liver fibrosis assessed using fibrosis-4 among patients with metabolic dysfunction-associated fatty liver disease
Muscle strength | OR (95%CI) | ||
Model 1 | Model 2 | Model 3 | |
1.3 ≤ FIB-4 < 2.67 | |||
Q1 | 2.67 (2.35–3.02) | 0.96 (0.82–1.12) | 1.03 (0.87–1.21) |
Q2–Q4 | 1 (reference) | 1 (reference) | 1 (reference) |
P value | < 0.001 | 0.588 | 0.773 |
Q1 | 4.09 (3.50–4.79) | 0.89 (0.72–1.09) | 1.01 (0.81–1.26) |
Q2 | 2.31 (2.00–2.66) | 0.85 (0.71–1.01) | 0.94 (0.78–1.13) |
Q3 | 1.67 (1.43–1.94) | 0.97 (0.81–1.16) | 1.04 (0.86–1.25) |
Q4 | 1 (reference) | 1 (reference) | 1 (reference) |
P for trend | < 0.001 | 0.117 | 0.809 |
FIB-4 ≥ 2.67 | |||
Q1 | 4.71 (3.38–6.56) | 1.72 (1.19–2.50) | 1.83 (1.25–2.69) |
Q2–Q4 | 1 (reference) | 1 (reference) | 1 (reference) |
P value | < 0.001 | 0.004 | 0.002 |
Q1 | 8.13 (4.74–13.95) | 1.68 (0.89–3.17) | 1.85 (0.92–3.74) |
Q2 | 2.25 (1.22–4.15) | 0.78 (0.41–1.47) | 0.82 (0.41–1.66) |
Q3 | 2.20 (1.18–4.13) | 1.26 (0.65–2.46) | 1.31 (0.65–2.65) |
Q4 | 1 (reference) | 1 (reference) | 1 (reference) |
P for trend | < 0.001 | 0.113 | 0.073 |
- Citation: Lee GB, Huh Y, Lee SH, Han B, Kim YH, Kim DH, Kim SM, Choi YS, Cho KH, Nam GE. Association of low muscle strength with metabolic dysfunction-associated fatty liver disease: A nationwide study. World J Gastroenterol 2023; 29(45): 5962-5973
- URL: https://www.wjgnet.com/1007-9327/full/v29/i45/5962.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i45.5962